The pulse of the work.

Five plastic surgery startups from the MTI/ASPS Plastic Surgery Accelerator propelled to finals of annual medtech competition

June 3, 2026

Boston’s Additive Edge: Wyss Institute’s New Spin-Out Advances Natural Breast Reconstruction

Feature coverage of ReConstruct Bio's bioprinting approach to vascularized tissue reconstruction.

May 22, 2026

Science Advances, 2019 foundational SWIFT paper

The peer-reviewed Science Advances paper introducing SWIFT (Sacrificial Writing Into Functional Tissue), the vascularization technology underlying the BioImplant.

May 22, 2026

A swifter way toward 3D-printed organs

Coverage of the SWIFT vascularization technology — the foundational platform behind the BioImplant.

May 22, 2026

Reimagine the World, vol. 4

The Wyss Institute's fourth edition of Reimagine the World highlights ReConstruct Bio's vascularized tissue platform.

May 22, 2026

The Wyss makes up for lost time with health innovation for women

How women’s health advocacy, data-driven technology innovation, cross-sector collaboration, and investment converge at the Wyss to help close the gender gap in healthcare

May 22, 2026

Building better breast reconstruction for cancer survivors

ReConstruct is leveraging patient-derived, vascularized tissue to improve the safety of breast reconstruction

May 22, 2026

Breast and soft tissue reconstructive surgery

Breast reconstruction and augmentation options are limited and come with significant health risks. Artificial silicone or saline implants must be replaced within 10 to 15 years.

May 22, 2026

ReConstruct: Vascularized Tissue for Breast Reconstruction and Augmentation

Adipose tissue assembled from a patient’s own cells and integrated into their body offer more natural breast reconstruction and augmentation with fewer health risks

May 22, 2026

Restoration Is Not Replacement

Why patient-derived tissue changes the meaning of reconstruction.

May 3, 2026